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Summary To examine the relationship between body weight and vascular invasion (VI) around tumours in post-menopausal women with
operable breast cancer, a retrospective study was conducted of 393 patients treated in a breast unit between 1987 and 1991. Weight was
measured at the time of diagnosis. Vascular invasion was recorded as being present or absent. Vascular invasion was seen in slightly more
of the 50 perimenopausal patients than in the 343 post-menopausal women (44% vs 36%). In the tumour specimens from post-menopausal
patients weighing <50 kg, VI was observed in 11% compared with 45% of those weighing more than 80 kg (P= 0.02). Furthermore, the 5-year
survival of those with VI was 74% compared with 91% for those without (P < 0.0001). Menopausal status and body weight may influence
survival in patients with breast cancer, possibly as a result of the presence of unopposed circulating oestrogens at the time of surgery.
Oestrogens may alter cohesiveness of breast cancer cells and modulate secretion of proteases, thereby influencing invasive potential.
Excision of tumours in such an environment may have a deleterious impact on survival.
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The prognosis ofwomen with operable breast cancerdepends upon
tumour type, axillary nodal involvement and also menopausal
status (Adami et al, 1986; Caleffi et al, 1989). Premenopausal
cases have the lowest hazard rates for relapse and death. Rates are
intermediate in post-menopausal women and the highest rates are
found in perimenopausal women, that is those within 5 years oflast
menstrual period (Langlands et al, 1989). The observed differences
may be due to the different hormonal environment to which
tumours are exposed in these three groups ofwomen.
Survival has been shown to be inversely related to body weight
in the majority of studies (Boyd et al, 1981; Tartter et al, 1981;
Newman et al, 1986; Tretli etal, 1990; Senie etal, 199la; Vatten et
al, 1991), but such a relationship is less obvious in premenopausal
women (Greenberg et al, 1985). Although there is a relation
between body weight and otherprognostic factors, such as tumour
size and axillary lymph node involvement, the effect of obesity
remains an independent factor in multivariate analysis (Tarttar et
al, 1981; Vatten et al, 1991). The mechanism through which
menopausal status and body weight influence survival is uncer-
tain, although it is known that most circulating oestrogens in post-
menopausal women are derived from peripheral aromatization of
adrenal androgens in subcutaneous fat. Thus, more obese women
have higher plasma levels of oestrogens (Grodin et al, 1973).
Additionally, the impact ofobesity on survival is more pronounced
among those women with oestrogen receptor-positive breast
cancers (Verreault et al, 1989).
The risk of relapse and death also depends upon the metastatic
potential ofthe tumour as manifested by the presence ofmalignant
Received 10 June 1996
Revised 1 October 1996
Accepted4 October 1996
Correspondence to: IS Fentiman
cells in lymphatic channels and blood vessels (vascular invasion,
VI), both in and round the primary lesion (Bettelheim et al, 1984;
Davis et al, 1985). For this reason, the relationship between
weight, height and vascular invasion has been examined in a series
ofpost-menopausal women with operable breast cancer.
MATERIALS AND METHODS
A consecutive series of post-menopausal women with operable
breast cancer treated at Guy's Hospital between 1987 and 1991
was studied. They were divided into two groups, perimenopausal
and post-menopausal. Perimenopausal women were defined as
those within 5 years of the last menstrual period (LMP). All
patients beyond 5 years of the LMP were grouped as post-
menopausal. Between 1987 and 1991, 460 such cases were seen,
but 60 were excluded from the analysis because they were on
steroid hormone treatment at the time of diagnosis. Data
concerning body weight and height were not available in seven
cases. Out of 393 eligible patients, 50 were perimenopausal and
343 were post-menopausal.
Height and weight were measured in metres and kilograms at
the time ofdiagnosis in all patients. Those with a primary tumour
< 4 cm were usually treated by a breast conservation procedure,
whereas those with larger tumours underwent a modified radical
mastectomy. Information on other prognostic factors such as
tumour size, type, grade and nodal involvement was available
from a computerized database.
Vascular invasion (VI) was defined as the presence ofmalignant
cells within an endothelium-lined space in or around a primary
breast cancer. No attempt was made to distinguish between
lymphatics and small blood vessels. The majority of slides were
reviewed by one pathologist (RRM) or by others under her direct
supervision. Haematoxylin and eosin-stained sections offormalin-
fixed tissue were examined and, in a few cases, methacam-fixed
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Figure 1 Overall survival of patients with or without vascular invasion. X2
17.54, P< 0.001
Table 1 Prognostic variables in perimenopausal and post-menopausal
women with operable breast cancer
Perimenopausal Post-menopausal
(n= 50) (n= 343)
Mean age + s.d. (years) 52.6 + 3.7 64.0 + 7.6**
Mean tumour size + s.d. (cm) 2.5 + 1.7 3.0 + 1.5*
Axillary nodal involvement (%) 26 (52) 152 (44)
Mean number of nodes + s.d. 3.2 + 6.2 2.5 + 6.1
Tumour type (%)
Ductal 37 (74) 244 (71)
Lobular 3 (6) 47 (14)
Other 10 (20) 52 (15)
Ductal tumour grade
(% of ductal)
1 ~~~~~~~5 (14) 37(15)
11 14(38) 122(50)
Ill 18 (49) 85 (35)
Differences not significant unless shown. .P = 0.04, Mann-Whitney test.
**P = «<0.001, Mann-Whitney test.
Table 2 Logistic regression analysis for predictability of VI
Variable (coding) Z-valuea P-value ORb
Nodes (0 vs 1-3 vs > 3) 5.4 «<0.0001 5.2
Weight (continuous) 4.1 <0.0001 5.0
Histology' (grade 1 vs 2 vs 3) 2.7 0.008 2.9
Height (continuous) 2.2 0.024 2.4
Standardized normal deviate. Odds ratio comparing extremes, i.e. 0
nodes vs >3 nodes, 50 kg vs 90 kg, grade 1 vs grade 3, 1.5 m vs 1.7 m.
cNon-ductal histologies included with grade 2. The following factors were
included in the analysis but did not reach statistical significance (P = 0.05):
menstrual status, tumour size and patient age.
Table 3 Univariate analysis of prognostic variables and survival
Variable Chi-square P-value
Menopausal status 3.6 0.58
Age 0.24 0.63
Tumour size 7.58 0.0059
Histological type/grade 8.12 0.0044
Axillary nodal status 12.07 0.0005
Vascular invasion 16.39 0.0001
Body massindex 0.58 0.45
tissue was also available. Between one and five slides were exam-
ined, depending on the size of the tumour. Suspicious areas were
always examined under high power for confirmation of the pres-
ence of vascular invasion. Only unequivocal foci were accepted.
Statistical methods
Non-parametric tests were used where possible. Correlation
coefficients, where given, are Spearman's rank correlation co-
efficients. Logistic regression analysis was used to investigate
multivariate correlates of vascular invasion. Survival curves were
drawn using the method ofKaplan and Meier (1985), with signifi-
cance being determined using the log-rank test (Peto et al, 1977).
Multivariate survival analysis used Cox's proportional hazards
model (Cox, 1976).
RESULTS
The distribution of conventional prognostic factors in peri-
menopausal and post-menopausal cases was not significantly
different, as shown in Table 1, with the exception that mean tumour
size was slightly larger in post-menopausal patients. Vascular inva-
sion was found in a greater proportion ofperimenopausal patients
than in post-menopausal cases (44% vs 36%), although this did not
reach statistical significance (P = 0.34). There was no significant
relation between weight and vascular invasion (VI) in peri-
menopausal women. In post-menopausal patients, median weight
for the group with vascular invasion was 69 kg (range 46-120 kg),
which was significantly greater than that of the group without
VI (63 kg, range 41-102 kg), P < 0.0001 (Mann-Whitney test).
Among lighter women with weight < 50 kg, VI was present in 11%
whereas, for heavier women weighing > 80 kg, it was observed in
45% ofcases (Fisher's exact test, P = 0.02).
Height was not correlated univariately with vascular invasion
and showed only a weak multivariate correlation, after allowance
for weight (Table 2). Further analysis using body mass index did
not show a greater correlation than the analysis using weight
alone. Multivariate logistic regression analyses demonstrated a
further strong correlation of VI with the number of lymph node
metastases and a weaker correlation with histological grade (Table
2). There was no significant relationship between oestrogen
receptor (ER) ofthe primary tumour and vascular invasion in the
whole group (Spearman rank correlation r = 0.098, P = 0.075) and,
similarly, in the post-menopausal cases only a weak relationship (r
= 0.12, P = 0.035). IfER was included in the Cox model, it was an
independent prognostic factor but, because of the number of
patients with unknown ER (n = 60), there was a significant reduc-
tion ofpatients included within the model from 380 without ER to
325 with ER included.
Univariate and multivariate predictors of survival are shown
in Table 3. Weight had no impact on survival. Vascular invasion
was the strongest predictor. Five-year survival for women with
VI was 74% compared with 91% for those without VI (%2 = 17.5,
P < 0.0001). When the Cox model was repeated, omitting VI,
weight was not a prognostic indicator in univariate or multivariate
analysis.
DISCUSSION
This study has shown that there is a highly significant relationship
between weight and vascular invasion in and around breast
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cancers in post-menopausal women. Heavier women are exposed
to higher levels of oestrogens as a result of peripheral aromatiza-
tion of androgen (Grodin et al, 1973; Hemsell et al, 1974). It is
possible that the observed increase in rate of vascular invasion
may be due to an effect of oestrogen on the primary tumour. It has
been shown previously that premenopausal women exposed to
unopposed oestrogen at the time of tumour excision have a worse
prognosis than that ofwomen undergoing surgery during the luteal
phase of the menstrual cycle (Badwe et al, 1991). The magnitude
of the effect in premenopausal women was similar in oestrogen
receptor-positive (ER+) and -negative (ER-) cases, suggesting that
this might result from activation ofER+ peritumoral normal tissue.
Similarly, in this study the ER status of the tumours did not have
any impact on vascular invasion or prognosis.
There is still no uniformity concerning these findings, which
have been confirmed by some (Hrushesky et al, 1989; Senie et al,
1991b; Ville et al, 1991) but not by others (Goldhirsch et al, 1991;
Low et al, 1991; Powles et al, 1991). However meta-analysis of
published studies has shown an overall significant effect oftiming
of surgery on both relapse-free and overall survival (Fentiman et
al, 1994). Furthermore, a recent study showed that vascular inva-
sion was observed in 47% of tumours excised between days 3 and
12 of the cycle but in only 33% of those undergoing surgery at
other times (Badwe et al, 1995). In vitro, oestrogens modulate
secretion of at least two proteases, plasminogen activator (Mira-y-
Lopez et al, 1991) and cathepsin D (Rochefort et al, 1990) which
can activate a cascade ofproteolysis (He et al, 1989). The ability to
secrete these proteases has been shown to be an independent
adverse predictor of survival in breast cancer (Rochefort, 1990;
Duffy et al, 1991 ).
Perimenopausal women experience infrequent ovulation and
those with breast cancers are more likely to be exposed to unop-
posed oestrogens at the time of surgery. Circulating oestradiol
levels in perimenopausal women are variable but can reach
premenopausal follicular levels. Once the ovaries have ceased to
produce active hormones, the major source of oestrogen is body
fat. It has been reported that women with breast cancer aged 50
years or over who have four or more axillary lymph node metas-
tases were more likely to be obese (Daniell et al, 1988).
Thus, unopposed oestrogens may induce secretion of proteases
which allow a more dyscohesive tumour to gain access to vascular
channels and hence attempts at surgical excision of the tumour
may be deleterious in such an environment. The data from this
study imply that tumour behaviour in post-menopausal women
may be modulated by oestrogens. Additionally, they suggest
avenues for further research with preoperative hormonal manipu-
lations in studies with both biological and clinical end points.
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